IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
44.861
+0.071 (+0.16%)
As of 10:13AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close44.790
Open44.670
Bid44.250 x 800
Ask44.340 x 900
Day's Range44.240 - 44.880
52 Week Range39.070 - 65.510
Volume40,201
Avg. Volume1,177,453
Market Cap5.631B
Beta3.29
PE Ratio (TTM)N/A
EPS (TTM)-0.131
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.25
Trade prices are not sourced from all markets
  • Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
    Zacksyesterday

    Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates

    It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS

  • Ionis’s Tegsedi Receives Marketing Authorization in Europe
    Market Realist7 days ago

    Ionis’s Tegsedi Receives Marketing Authorization in Europe

    Ionis Pharmaceuticals (IONS) and Akcea Therapeutics (AKCA) announced yesterday that the European Commission had approved their marketing authorization application for Tegsedi (inotersen), an antisense oligonucleotide inhibitor that blocks the production of transthyretin protein, for the treatment of stage 1 and stage 2 polyneuropathy in patients with hereditary transthyretin amyloidosis.

  • Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer
    Zacks7 days ago

    Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer

    Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.

  • Is Ionis Pharmaceuticals, Inc. a Buy?
    Motley Fool7 days ago

    Is Ionis Pharmaceuticals, Inc. a Buy?

    One successful drug on the market. Two potential approvals on the way. Six big partners. But do the numbers add up to buying Ionis right now?

  • Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%
    Zacks8 days ago

    Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%

    Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • GlobeNewswire8 days ago

    Akcea and Ionis Announce Approval of TEGSEDI(TM) (inotersen) in the European Union

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that TEGSEDITM (inotersen) has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). This follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA). Click here to view the EC`s decision.

  • GlobeNewswire8 days ago

    Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that TEGSEDITM (inotersen) has received marketing authorization approval from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). This follows the positive opinion recommending approval provided by the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA).

  • ACCESSWIRE8 days ago

    Free Technical Research on Intrexon and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.

  • Analysts’ Estimates and Recommendations for Ionis
    Market Realist10 days ago

    Analysts’ Estimates and Recommendations for Ionis

    As discussed previously, analysts expect Ionis Pharmaceuticals’ (IONS) revenue to grow YoY (year-over-year) in 30.6% YoY to $136.0 million in Q2 2018. They expect the company to report an adjusted net loss of $24.3 million due to higher SG&A (selling, general, and administrative) and R&D (research and development) expenses, resulting in a loss per share of $0.09. The chart below shows analysts’ recommendations for Pfizer stock over the last 12 months.

  • A Review of Ionis’s Revenue Stream
    Market Realist10 days ago

    A Review of Ionis’s Revenue Stream

    As discussed earlier, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) in Q1 2018, and analysts expect it to grow 30.6% YoY to $136.0 million in Q2 2018. The graph below shows Ionis’s commercial and R&D (research and development) revenue since Q1 2017.

  • ACCESSWIRE10 days ago

    Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Ionis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 9, 2018 / U.S. equities posted solid gains on Friday, ending the week on a positive note, supported by a stronger-than-expected jobs report. The Dow Jones Industrial Average ...

  • Ionis’s Quarterly Revenue Trends
    Market Realist10 days ago

    Ionis’s Quarterly Revenue Trends

    Ionis Pharmaceuticals (IONS) has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. As mentioned in the previous part, Ionis’s revenue grew 24.7% YoY (year-over-year) in Q1 2018. The chart below shows Ionis’s revenue since Q1 2017, and analysts’ estimate for Q2 2018. 

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit12 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Short interest is moderately high for IONS with between 10 and 15% of shares outstanding currently on loan. The net inflows of $2.42 billion over the last one-month into ETFs that hold IONS are not among the highest of the last year and have been slowing.

  • How Ionis Pharmaceuticals’ Valuation Compares
    Market Realist13 days ago

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), an RNA1-targeted therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies. In Q1 2018, Ionis’s revenue grew 24.7% YoY (year-over-year) to $144.4 million from $115.8 million.

  • The Wall Street Journal13 days ago

    [$$] Dynacure Pumps War Chest to Beat Rare Muscle Diseases

    Venture capitalists are betting 47 million euros ($55 million) that French startup Dynacure can keep up recent momentum in the battle against rare muscle diseases.

  • Why This Biotech Company 'Dominates' Its Rival In Drug Study
    Investor's Business Daily14 days ago

    Why This Biotech Company 'Dominates' Its Rival In Drug Study

    Alnylam seemingly outperformed rival Ionis in tests of drugs to treat a progressive rare disease, an analyst said Thursday. Both biotech companies are making treatments for a condition known as hereditary ATTR amyloidosis.

  • PR Newswire14 days ago

    New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

    Results from the study demonstrated that patients treated with TEGSEDI experienced early, sustained and highly significant benefit in both co-primary endpoints:  the modified Neuropathy Impairment Score +7 (mNIS+7), a measure of neuropathic disease progression, and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN), compared to placebo-treated patients. The clinical benefits demonstrated by TEGSEDI were associated with substantial reductions in the transthyretin (TTR) protein, the underlying cause of hATTR amyloidosis.  For the full text of this publication, please visit: https://www.nejm.org/doi/full/10.1056/NEJMoa1716793.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit16 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Short interest is moderately high for IONS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 20. The net inflows of $3.45 billion over the last one-month into ETFs that hold IONS are among the highest of the last year, but the rate of growth is slowing.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit26 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS

  • Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs
    Investor's Business Daily29 days ago

    Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs

    PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.

  • Don't Get Too Excited About PTC Therapeutics (Yet)
    Motley Fool29 days ago

    Don't Get Too Excited About PTC Therapeutics (Yet)

    PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.

  • Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
    Market Realistlast month

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial

  • How Financially Strong Is Ionis Pharmaceuticals Inc (NASDAQ:IONS)?
    Simply Wall St.last month

    How Financially Strong Is Ionis Pharmaceuticals Inc (NASDAQ:IONS)?

    Mid-caps stocks, like Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a market capitalization of US$5.85B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...

  • Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle
    Motley Foollast month

    Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle

    Investors value a new round of data for PTC's spinal muscular atrophy drug.